Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Biogen Background Information (This description is provided by the company.) At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide ...

Biogen Background Information (This description is provided by the company.) At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide ...

“At Biogen Digital Health we have a full team dedicated to patient experience and user insights,” he said. “Their mission is to start from the need, improve the experience, and iterate.

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

so we don't think Biogen has been destroying significant value via share buybacks. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.